Laboratory Medicine ›› 2021, Vol. 36 ›› Issue (3): 275-280.DOI: 10.3969/j.issn.1673-8640.2021.03.009
Previous Articles Next Articles
WANG Bin
Received:
2020-04-21
Online:
2021-03-30
Published:
2021-03-30
CLC Number:
WANG Bin. Correlation between neutrophil-to-lymphocyte ratio and short-term poor prognosis in patients with corona virus disease 2019[J]. Laboratory Medicine, 2021, 36(3): 275-280.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2021.03.009
组别 | 例数 | WBC计数/(×109/L) | NEUT#/(×109/L) | LYMPH#/(×109/L) | PLT计数/(×109/L) | NLR | PLR |
---|---|---|---|---|---|---|---|
COVID-19组 | 302 | 5.56(4.20~7.62) | 4.21(2.71~6.08) | 0.83(0.57~1.19) | 188(144~253) | 4.82(2.77~8.68) | 211.97(159.49~341.33) |
对照组 | 57 | 5.20(4.33~6.06) | 2.74(2.32~3.53) | 1.78(1.56~2.19) | 229(194~262) | 1.42(1.12~2.05) | 117.45(93.85~147.62) |
统计值 | -1.076 | -5.283 | -10.623 | -3.505 | -9.773 | -8.417 | |
P值 | 0.282 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | WBC计数/(×109/L) | NEUT#/(×109/L) | LYMPH#/(×109/L) | PLT计数/(×109/L) | NLR | PLR |
---|---|---|---|---|---|---|---|
COVID-19组 | 302 | 5.56(4.20~7.62) | 4.21(2.71~6.08) | 0.83(0.57~1.19) | 188(144~253) | 4.82(2.77~8.68) | 211.97(159.49~341.33) |
对照组 | 57 | 5.20(4.33~6.06) | 2.74(2.32~3.53) | 1.78(1.56~2.19) | 229(194~262) | 1.42(1.12~2.05) | 117.45(93.85~147.62) |
统计值 | -1.076 | -5.283 | -10.623 | -3.505 | -9.773 | -8.417 | |
P值 | 0.282 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | 男性/例(%) | 年龄/岁 | 高血压/例(%) | 糖尿病/例(%) | 冠心病/例(%) | 结核病史/例(%) | 死亡/例(%) |
---|---|---|---|---|---|---|---|---|
非重症组 | 218 | 99(45.41) | 57.50(44.00~67.00) | 59(27.06) | 27(12.39) | 13(5.96) | 4(1.83) | 4(1.83) |
重症组 | 84 | 55(65.48) | 65.00(56.75~72.25) | 33(39.29) | 15(17.86) | 8(9.52) | 3(3.57) | 29(34.52) |
统计值 | 9.767 | -4.369 | 4.275 | 1.516 | 1.188 | 0.223 | 27.414 | |
P值 | 0.002 | <0.001 | 0.039 | 0.218 | 0.276 | 0.637 | <0.001 | |
组别 | WBC计数/(×109/L) | NEUT#/(×109/L) | LYMPH#/(×109/L) | PLT计数/(×109/L) | ||||
非重症组 | 5.25(3.99~6.70) | 3.84(2.51~5.12) | 0.91(0.67~1.29) | 192(148~264) | ||||
重症组 | 7.58(5.02~12.19) | 6.43(3.94~11.41) | 0.56(0.40~0.93) | 171(123~242) | ||||
统计值 | -6.169 | -7.188 | -6.251 | -2.080 | ||||
P值 | <0.001 | <0.001 | <0.001 | 0.038 | ||||
组别 | NLR | PLR | hs-CRP/(mg/L) | PCT /(ng/mL) | ||||
非重症组 | 3.98(2.38~6.48) | 202.47(152.36~293.65) | 44.90(13.75~81.25) | 0.05(0.03~0.10) | ||||
重症组 | 12.34(5.87~25.13) | 309.08(187.29~478.34) | 105.60(53.33~172.95) | 0.20(0.09~0.55) | ||||
统计值 | -8.694 | -4.440 | -6.394 | -7.986 | ||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | 男性/例(%) | 年龄/岁 | 高血压/例(%) | 糖尿病/例(%) | 冠心病/例(%) | 结核病史/例(%) | 死亡/例(%) |
---|---|---|---|---|---|---|---|---|
非重症组 | 218 | 99(45.41) | 57.50(44.00~67.00) | 59(27.06) | 27(12.39) | 13(5.96) | 4(1.83) | 4(1.83) |
重症组 | 84 | 55(65.48) | 65.00(56.75~72.25) | 33(39.29) | 15(17.86) | 8(9.52) | 3(3.57) | 29(34.52) |
统计值 | 9.767 | -4.369 | 4.275 | 1.516 | 1.188 | 0.223 | 27.414 | |
P值 | 0.002 | <0.001 | 0.039 | 0.218 | 0.276 | 0.637 | <0.001 | |
组别 | WBC计数/(×109/L) | NEUT#/(×109/L) | LYMPH#/(×109/L) | PLT计数/(×109/L) | ||||
非重症组 | 5.25(3.99~6.70) | 3.84(2.51~5.12) | 0.91(0.67~1.29) | 192(148~264) | ||||
重症组 | 7.58(5.02~12.19) | 6.43(3.94~11.41) | 0.56(0.40~0.93) | 171(123~242) | ||||
统计值 | -6.169 | -7.188 | -6.251 | -2.080 | ||||
P值 | <0.001 | <0.001 | <0.001 | 0.038 | ||||
组别 | NLR | PLR | hs-CRP/(mg/L) | PCT /(ng/mL) | ||||
非重症组 | 3.98(2.38~6.48) | 202.47(152.36~293.65) | 44.90(13.75~81.25) | 0.05(0.03~0.10) | ||||
重症组 | 12.34(5.87~25.13) | 309.08(187.29~478.34) | 105.60(53.33~172.95) | 0.20(0.09~0.55) | ||||
统计值 | -8.694 | -4.440 | -6.394 | -7.986 | ||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | 男性/例(%) | 年龄/岁 | 高血压/ 例(%) | 糖尿病/ 例(%) | 冠心病/ 例(%) | 结核病史/ 例(%) | 院内生存时间/d |
---|---|---|---|---|---|---|---|---|
生存组 | 269 | 129(47.96) | 58.00(46.00~67.00) | 78(29.00) | 35(13.01) | 16(5.95) | 6(2.23) | 27(19~36) |
病亡组 | 33 | 25(75.76) | 69.00(62.50~77.00) | 14(42.42) | 7(21.21) | 5(15.15) | 1(3.03) | 9(5~14) |
统计值 | 9.092 | -5.717 | 2.502 | 1.037 | 2.557 | 0.000 | -9.600 | |
P值 | 0.003 | <0.001 | 0.114 | 0.308 | 0.110 | 1.000 | <0.001 | |
组别 | WBC计数/(×109/L) | NEUT#/(×109/L) | LYMPH#/(×109/L) | PLT计数/(×109/L) | ||||
生存组 | 5.36(4.11~6.85) | 3.93(2.61~5.41) | 0.89(0.64~1.25) | 198.00(151.00~261.00) | ||||
病亡组 | 9.05(5.23~13.56) | 7.99(4.19~12.47) | 0.50(0.36~0.85) | 158.00(115.50~213.00) | ||||
统计值 | -5.287 | -6.059 | -5.386 | -4.134 | ||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | ||||
组别 | NLR | PLR | hs-CRP/(mg/L) | PCT /(ng/mL) | ||||
生存组 | 4.20(2.46~7.07) | 207.37(159.18~319.18) | 46.40(16.20~92.75) | 0.06(0.03~0.12) | ||||
病亡组 | 13.54(6.44~28.48) | 256.25(182.92~458.77) | 102.10(54.70~180.50) | 0.23(0.11~0.60) | ||||
统计值 | -7.341 | -2.446 | -4.946 | -7.261 | ||||
P值 | <0.001 | 0.014 | <0.001 | <0.001 |
组别 | 例数 | 男性/例(%) | 年龄/岁 | 高血压/ 例(%) | 糖尿病/ 例(%) | 冠心病/ 例(%) | 结核病史/ 例(%) | 院内生存时间/d |
---|---|---|---|---|---|---|---|---|
生存组 | 269 | 129(47.96) | 58.00(46.00~67.00) | 78(29.00) | 35(13.01) | 16(5.95) | 6(2.23) | 27(19~36) |
病亡组 | 33 | 25(75.76) | 69.00(62.50~77.00) | 14(42.42) | 7(21.21) | 5(15.15) | 1(3.03) | 9(5~14) |
统计值 | 9.092 | -5.717 | 2.502 | 1.037 | 2.557 | 0.000 | -9.600 | |
P值 | 0.003 | <0.001 | 0.114 | 0.308 | 0.110 | 1.000 | <0.001 | |
组别 | WBC计数/(×109/L) | NEUT#/(×109/L) | LYMPH#/(×109/L) | PLT计数/(×109/L) | ||||
生存组 | 5.36(4.11~6.85) | 3.93(2.61~5.41) | 0.89(0.64~1.25) | 198.00(151.00~261.00) | ||||
病亡组 | 9.05(5.23~13.56) | 7.99(4.19~12.47) | 0.50(0.36~0.85) | 158.00(115.50~213.00) | ||||
统计值 | -5.287 | -6.059 | -5.386 | -4.134 | ||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | ||||
组别 | NLR | PLR | hs-CRP/(mg/L) | PCT /(ng/mL) | ||||
生存组 | 4.20(2.46~7.07) | 207.37(159.18~319.18) | 46.40(16.20~92.75) | 0.06(0.03~0.12) | ||||
病亡组 | 13.54(6.44~28.48) | 256.25(182.92~458.77) | 102.10(54.70~180.50) | 0.23(0.11~0.60) | ||||
统计值 | -7.341 | -2.446 | -4.946 | -7.261 | ||||
P值 | <0.001 | 0.014 | <0.001 | <0.001 |
变量 | 偏回归系数 | 标准误 | Wald值 | 自由度 | P值 | OR值 | 95% CI |
---|---|---|---|---|---|---|---|
男性 | 0.994 | 0.424 | 5.485 | 1 | 0.019 | 2.702 | 1.176~6.208 |
年龄 | 0.074 | 0.018 | 17.295 | 1 | <0.001 | 1.077 | 1.040~1.115 |
NEUT# | 0.189 | 0.087 | 4.745 | 1 | 0.029 | 1.208 | 1.019~1.431 |
PLT计数 | -0.009 | 0.003 | 9.351 | 1 | 0.002 | 0.991 | 0.985~0.997 |
NLR | 0.057 | 0.027 | 4.428 | 1 | 0.035 | 1.058 | 1.004~1.115 |
变量 | 偏回归系数 | 标准误 | Wald值 | 自由度 | P值 | OR值 | 95% CI |
---|---|---|---|---|---|---|---|
男性 | 0.994 | 0.424 | 5.485 | 1 | 0.019 | 2.702 | 1.176~6.208 |
年龄 | 0.074 | 0.018 | 17.295 | 1 | <0.001 | 1.077 | 1.040~1.115 |
NEUT# | 0.189 | 0.087 | 4.745 | 1 | 0.029 | 1.208 | 1.019~1.431 |
PLT计数 | -0.009 | 0.003 | 9.351 | 1 | 0.002 | 0.991 | 0.985~0.997 |
NLR | 0.057 | 0.027 | 4.428 | 1 | 0.035 | 1.058 | 1.004~1.115 |
指标 | AUC | 标准误 | P值 | 95%CI |
---|---|---|---|---|
NEUT# | 0.763 | 0.0402 | <0.001 | 0.685~0.841 |
PLT计数 | 0.680 | 0.0404 | <0.001 | 0.624~0.732 |
NLR | 0.819 | 0.0324 | <0.001 | 0.756~0.882 |
指标 | AUC | 标准误 | P值 | 95%CI |
---|---|---|---|---|
NEUT# | 0.763 | 0.0402 | <0.001 | 0.685~0.841 |
PLT计数 | 0.680 | 0.0404 | <0.001 | 0.624~0.732 |
NLR | 0.819 | 0.0324 | <0.001 | 0.756~0.882 |
[1] |
GUAN W J, NI Z Y, HU Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020,382(18):1708-1720.
DOI URL PMID |
[2] |
BUCHHOLZ U J, WARD J M LAMIRANDE E W, et al. Deletion of nonstructural proteins NS1 and NS2 from pneumonia virus of mice attenuates viral replication and reduces pulmonary cytokine expression and disease[J]. J Virol, 2009,83(4):1969-1980.
URL PMID |
[3] |
GAZI E, BAYRAM B, GAZI S, et al. Prognostic value of the neutrophil-lymphocyte ratio in patients with ST-elevated acute myocardial infarction[J]. Clin Appl Thromb Hemost, 2015,21(2):155-159.
DOI URL PMID |
[4] |
SURENDAR J, INDULEKHA K, MOHAN V, et al. Association of neutrophil-lymphocyte ratio with metabolic syndrome and its components in Asian Indians(CURES-143)[J]. J Diabetes Complications, 2016,30(8):1525-1529.
URL PMID |
[5] | ROSSI S, BASSO M, STRIPPOLI A, et al. Are markers of systemic inflammation good prognostic indicators in colorectal cancer?[J]. Clin Colorectal Cancer, 2017,16(4):264-274. |
[6] | 国家卫生健康委办公厅. 新型冠状病毒肺炎诊疗方案(试行第八版)[EB/OL]. (2020-08-19)[2020-08-23]. http://www.nhc.gov.cn/yzygj/s7653p/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a/files/a449a3e2e2c94d9a856d5faea2ff0f94.pdf. |
[7] |
YANG X, YU Y, XU J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,China:a single-centered retrospective observational study[J]. Lancet Respir Med, 2020,8(5):475-481.
DOI URL PMID |
[8] |
REMICK D G. Pathophysiology of sepsis[J]. Am J Pathol, 2007,170(5):1435-1444.
URL PMID |
[9] |
STEARNS-KUROSAWA D J, OSUCHOWSKI M F, VALENTINE C, et al. The pathogenesis of sepsis[J]. Annu Rev Pathol, 2011,6:19-48.
DOI URL PMID |
[10] |
XU Z, SHI L, WANG Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020,8(4):420-422.
DOI URL PMID |
[11] | 朱星成, 段勇, 黄革联, 等. PCT、hs-CRP、SAA对细菌与病毒感染的鉴别作用[J]. 国际检验医学杂志, 2014,35(22):3048-3050. |
[12] | 梁涛, 杨诚, 吴苏源, 等. 多项指标联合检测在细菌感染性疾病中的诊断价值[J]. 临床血液学杂志, 2019,32(12):905-908. |
[13] | ZHAO C, WEI Y, CHEN D, et al. Prognostic value of an inflammatory biomarker-based clinical algorithm in septic patients in the emergency department:an observational study[J]. Int Immunopharmacology, 2020,80:106145. |
[14] | 张培杰, 许铁. 中性粒细胞/淋巴细胞比值对脓毒症患者病情严重程度及预后的评估和预测价值[J]. 中国急救复苏及灾害医学杂志, 2018,13(7):642-647. |
[15] | 许剑云, 许福祥, 朱一川, 等. 外周血中性粒细胞/淋巴细胞比值动态监测对细菌性脓毒症患者病情及预后的评估价值[J]. 中国综合临床, 2017,33(2):130-133. |
[16] |
LIU J, LIU Y, XIANG P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage[J]. J Transl Med, 2020,18(1):206.
URL PMID |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||